NXP800
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
Trial Timeline
Dec 31, 2021 → Dec 1, 2025
NCT ID
NCT05226507About NXP800
NXP800 is a phase 1 stage product being developed by Nuvectis Pharma for Advanced Solid Tumor. The current trial status is active. This product is registered under clinical trial identifier NCT05226507. Target conditions include Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05226507 | Phase 1 | Active |
Competing Products
20 competing products in Advanced Solid Tumor